Monoclonal Antibody

单克隆抗体

基本信息

项目摘要

Monoclonal antibodies have become an essential tool in biochemistry, molecular biology, and medicine, and basic and clinical investigators have been using them widely for research, diagnosis, and clinical therapy. The Monoclonal Antibodies Facility (MABF) was formally established in 2003. Its main goal is to produce high-affinity antibodies in a high-throughput and effective manner, while concentrating on quality of product and service. The MABF minimizes extensive hands-on procedures and standardizes protocols to provide accurate results and reproducibility. Specific aims and long-term objectives are: 1) to produce high-affinity custom monoclonal antibodies for a wide range of research projects; 2) to enable investigators to access highly-experienced personnel in hybridoma production and methodologies, and trouble-shoot any antigen or screening-related issues; 3) to provide quality services at competitive prices; 4) to gain insight, by means of the generated antibodies, into the role that different molecules play in normal and pathological systems, and characterize them for eventual therapy or diagnosis. The MABF occupies 726 sq. ft. in SCRB 1, home to the Center for Cancer Immunology Research (CCIR) on the South Campus which is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tanks rooms, and glassware washing and sterilization facilities, all of which are available to the MABF. The MABF staff consists of Michel Gilliet, MD, Core Leader, is responsible for the direction of the core and chairs the oversight committee. Dr. Gilliet meets with Dr. Bover and Long Vien regularly concerning the overall operation of the MABF. Laura Bover, PhD, Core Co-Leader, is responsible for the overall operation of the MABF, for progress reports, interest researchers in the use of the facility and assures that procedural and policy changes are vetted with the oversight committee. She is responsible together with Long Vien of the short- and long-term planning and growth of the facility. Long Vien, Core Manager, is responsible for the day-to-day operations of the core. Together with Dr. Bover, he plans and designs technical procedures for the different user requirements. James Wygant, Coordinator Research Laboratory, is responsible for technical procedures and makes the first contact with users. He records all activities of the facility and follows-up with users, gathering information pertaining to publications, and grants used to cover the services. Rosa Munoz, Research Assistant, is responsible for technical procedures (hands-on). Future plans are to redesign our website to provide more information on services and benefits in an effort to reach more researchers inside MDACC. The facility also needs to communicate more broadly about the unique value-added features of its services.
单克隆抗体已成为生物化学、分子生物学和医学中的重要工具, 基础和临床研究者已经广泛地将它们用于研究、诊断和临床治疗。 单克隆抗体机构(MABF)于2003年正式成立。其主要目标是生产 以高通量和有效的方式生产高亲和力抗体,同时专注于产品质量 和服务MABF最大限度地减少了大量的动手操作程序,并简化了方案, 准确的结果和重现性。具体目标和长远目标是:1)产生高亲和力 定制单克隆抗体用于广泛的研究项目; 2)使研究人员能够访问 在杂交瘤生产和方法学方面经验丰富的人员,并解决任何抗原或 筛选相关问题; 3)以具有竞争力的价格提供优质服务; 4)通过 产生的抗体,不同的分子在正常和病理系统中发挥的作用, 为最终的治疗或诊断进行表征。MABF占地726平方米。英尺在SCRB 1中, 位于南校区的癌症免疫学研究中心(CCIR)配备了定制的 实验室服务、集中组织培养室、液氮罐室和玻璃器皿清洗 和灭菌设施,所有这些都可供MABF使用。MABF的工作人员包括Michel Gilliet, MD,核心领导者,负责核心的方向,并主持监督委员会。吉利特医生 定期与Bover博士和Long Vien会面,讨论MABF的整体运作。劳拉·博佛, 博士,核心联合领导人,负责MABF的整体运作,进度报告,兴趣 研究人员在使用该设施,并确保程序和政策的变化是审查与 监督委员会。她与Long Vien一起负责短期和长期规划, 设施的增长。核心经理Long Vien负责核心的日常营运。 他与Bover博士一起,为不同的用户需求规划和设计技术程序。 研究实验室协调员James Wygant负责技术程序,并制定 第一次接触用户。他记录设施的所有活动,并跟踪用户,收集 与出版物有关的信息,以及用于支付服务的赠款。Rosa Munoz,研究部 助理,负责技术程序(动手)。未来的计划是重新设计我们的网站, 提供更多关于服务和福利的信息,以努力接触更多的MDACC研究人员。 该设施还需要更广泛地宣传其服务的独特增值功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michel Gilliet其他文献

Michel Gilliet的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michel Gilliet', 18)}}的其他基金

Monoclonal Antibody
单克隆抗体
  • 批准号:
    7695945
  • 财政年份:
    2008
  • 资助金额:
    $ 8.82万
  • 项目类别:
Activation of Intratumoral pDCs by Tumor Self-DNA Coupled with Anti-microbial
肿瘤自身 DNA 联合抗菌药物激活瘤内 pDC
  • 批准号:
    7910573
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:
Activation of Intratumoral pDCs by Tumor Self-DNA Coupled with Anti-microbial
肿瘤自身 DNA 联合抗菌药物激活瘤内 pDC
  • 批准号:
    8382645
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:
Activation of Intratumoral pDCs by Tumor Self-DNA Coupled with Anti-microbial
肿瘤自身 DNA 联合抗菌药物激活瘤内 pDC
  • 批准号:
    8332331
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:
Monoclonal Antibody
单克隆抗体
  • 批准号:
    8379489
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:
Monoclonal Antibody
单克隆抗体
  • 批准号:
    8530392
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:
Activation of Intratumoral pDCs by Tumor Self-DNA Coupled with Anti-microbial
肿瘤自身 DNA 联合抗菌药物激活瘤内 pDC
  • 批准号:
    8135420
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:
Monoclonal Antibody
单克隆抗体
  • 批准号:
    8310874
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:
Monoclonal Antibody
单克隆抗体
  • 批准号:
    8144422
  • 财政年份:
  • 资助金额:
    $ 8.82万
  • 项目类别:

相似海外基金

Early clinial trials for Angelica herbal supplements for prostate cancer interception
当归草药补充剂拦截前列腺癌的早期临床试验
  • 批准号:
    10366646
  • 财政年份:
    2022
  • 资助金额:
    $ 8.82万
  • 项目类别:
Development of quality evaluation for establishing optimal cultivation conditions for medicinal plants, Japanese Angelica Root.
开发质量评价以建立药用植物日本当归的最佳栽培条件。
  • 批准号:
    20K06004
  • 财政年份:
    2020
  • 资助金额:
    $ 8.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of a cultivation conditions and quality evaluation aimed at the stable supply of high quality Japanese Angelica Root
旨在稳定供应优质当归的栽培条件的建立和质量评价
  • 批准号:
    15K18893
  • 财政年份:
    2015
  • 资助金额:
    $ 8.82万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
  • 批准号:
    9175121
  • 财政年份:
    2015
  • 资助金额:
    $ 8.82万
  • 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
  • 批准号:
    9044040
  • 财政年份:
    2012
  • 资助金额:
    $ 8.82万
  • 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
  • 批准号:
    8700324
  • 财政年份:
    2012
  • 资助金额:
    $ 8.82万
  • 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
  • 批准号:
    8547743
  • 财政年份:
    2012
  • 资助金额:
    $ 8.82万
  • 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
  • 批准号:
    8368398
  • 财政年份:
    2012
  • 资助金额:
    $ 8.82万
  • 项目类别:
Mechanisms of prostate cancer prevention by Korean Angelica
韩国当归预防前列腺癌的机制
  • 批准号:
    8867146
  • 财政年份:
    2012
  • 资助金额:
    $ 8.82万
  • 项目类别:
Molecular mechanisms of Angelica sinensis (Oliv.) Diels in women's health
当归对女性健康的分子机制
  • 批准号:
    7812964
  • 财政年份:
    2009
  • 资助金额:
    $ 8.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了